01 Gene Synthesis Is Moving toward More Complex Therapeutic Research The Gene Synthesis Market is shifting from basic research constructs toward increasingly complex sequences used in synthetic biology and advanced therapeutic research. Synthetic gene circuits are also becoming more sophisticated, allowing researchers to study programmable biological functions rather than single genes alone. A 2025 scientific review highlighted applications of synthetic gene circuits in solid tumors, immune regulation, and metabolic diseases, while identifying AI-driven optimization and advanced delivery platforms as important future directions. This expands demand for specialized, high-quality synthesis services. In October 2025, researchers published a review describing the growing clinical potential of synthetic gene circuits for cell and gene therapies, including applications in cancer and metabolic disease.
01 Expansion of Cell and Gene Therapies Is Increasing Synthetic DNA Demand The continued development of cell and gene therapies is a major driver for gene synthesis services. These programs require precisely characterized genetic materials during discovery, vector design, assay development, manufacturing research, and quality testing. As more therapies progress from laboratories toward commercial use, biotechnology companies need dependable suppliers capable of supporting increasingly demanding research and development workflows. Regulatory progress also demonstrates that genetic medicines are moving beyond a small number of early products. In January 2026, the FDA stated that its Center for Biologics Evaluation and Research had approved close to 50 cell and gene therapies over the previous decade, demonstrating the expanding commercial and clinical ecosystem supporting genetic technologies.
01 Biosecurity Compliance Adds Cost and Operational Complexity Stronger biosecurity requirements can restrain smaller gene synthesis providers because commercial operations increasingly require customer verification, sequence screening, documentation, and compliance processes in addition to manufacturing DNA accurately. Building automated screening infrastructure requires software, trained personnel, databases, security controls, and procedures for handling orders that require additional review. These requirements can raise operating costs and lengthen some transactions, particularly for companies serving research institutions subject to government procurement policies. However, screening is becoming essential for maintaining responsible access to synthetic nucleic acids. The result is a higher compliance barrier for new suppliers and potentially greater competitive advantages for established providers that already operate mature quality, security, and order-review systems.
01 Rare-Disease Therapies Are Expanding High-Value Research Applications Rare genetic diseases create an important opportunity because many are caused by specific mutations that can increasingly be studied through precisely designed genetic sequences. Synthetic genes can support early research, disease models, analytical standards, vector development, and other controlled development activities for highly targeted therapies. As regulatory agencies create more flexible pathways for treatments addressing small patient populations, biotechnology developers may pursue conditions that previously attracted limited commercial research. This creates opportunities for synthesis companies capable of supplying high-quality research materials with strong documentation and consistency. The opportunity is especially valuable because rare-disease programs often require specialized rather than commodity genetic materials, increasing the importance of technical support and quality assurance.
01 Therapeutic Safety Requirements Raise the Quality Bar for Genetic Materials A major challenge is meeting the increasingly demanding quality expectations surrounding genetic medicines. Synthetic DNA used during therapeutic research must support reliable downstream testing, while developers need strong controls over identity, consistency, manufacturing changes, and analytical methods. As therapies become more complex, regulators are also paying closer attention to safety evaluation and manufacturing evidence. The challenge is not limited to obtaining regulatory approval; safety findings can lead to additional monitoring or restrictions after commercialization. Gene synthesis suppliers serving this ecosystem therefore need robust quality systems and consistent materials, while therapy developers must connect genetic design with careful manufacturing and clinical risk assessment throughout development and commercialization.
August 2025 GenScript Biotech expanded its global gene synthesis and molecular biology services portfolio by enhancing its synthetic DNA production capabilities. The company focused on supporting applications in cell and gene therapy, vaccine development, protein engineering, and biotechnology research.
July 2025 Thermo Fisher Scientific expanded its synthetic biology and genetic engineering capabilities through advancements in GeneArt™ gene synthesis services. The company continued developing customized DNA design and synthesis solutions to support pharmaceutical, biotechnology, and academic research workflows.
June 2025 Integrated DNA Technologies (IDT), a Danaher company, expanded its synthetic biology offerings with improvements to custom gene synthesis and next-generation sequencing support services. The company focused on increasing accessibility to high-quality synthetic DNA solutions for research and biotechnology applications.
May 2025 Twist Bioscience expanded its synthetic biology portfolio by enhancing its gene synthesis and DNA manufacturing capabilities. The company continued investing in high-throughput DNA synthesis technologies to support applications in drug discovery, synthetic biology, therapeutics development, and academic research.